Biosimilar Medication Formulary Updates

Sep. 2025Pharmacy Updates

Updates to formulary biosimilar medications for denosumab, eculizumab, and ustekinumab products

In ongoing efforts to improve the value and affordability of health care benefits for our members, UPMC Health Plan has implemented biosimilar medication formulary updates for denosumab, eculizumab, and ustekinumab products. Effective dates for these changes are as follows.

  • UPMC for Life (Medicare/Special Needs Plan):
    • Part D formularies effective Sept. 1, 2025
    • Part B policies effective Sept. 10, 2025
  • UPMC Health Plan (Commercial/Exchange) and UPMC for Kids (CHIP): Formularies effective Oct. 1, 2025
  • UPMC for You and UPMC CHC: Effective Oct. 1, 2025

For full details on these changes, please refer to pages 18-19 in the September 2025 edition of Provider Partner Update.

Recent Announcements

Clinical workflow changes through Epic®

Changes are coming for network providers that utilize Provider OnLine to submit specific information to UPMC Health Plan. Select activities that were previously completed in Provider OnLine will now transition to UPMC Health Plan Tapestry Link.
Sep. 2026Important Notices

CME Webinar: Lifestyle Medicine in Practice: Evidence‑Based Strategies for Chronic Disease Care

Please join us for a live, CME-accredited webinar on Wednesday, Sept. 23 from noon to 1 p.m., that will provide an overview on lifestyle medicine. Participants will learn how to integrate six core domains—nutrition, physical activity, sleep, stress management, avoidance of risky substances, and social connection—into routine care using practical tools such as brief counseling, motivational interviewing, and team-based strategies.
Sep. 2026Education/Webinars

Voluntary nationwide recall: Thyroid (Vitruvias – August 2026)

Vitruvias Therapeutics Inc. is recalling one lot, lot 504950, of Thyroid Tablets, USP 30 mg. Thyroid Tablet is used to treat hypothyroidism (underactive thyroid).
Sep. 2026Pharmacy Updates